Rinvoq® - 202110


Active substance
upadacitinib
Holder AbbVie Belgium sa/nv
Status Running
Indication patients (adults and adolescents ≥ 12 years old) with severe atopic dermatitis who have no other suitable treatment option and are not eligible to participate in a clinical study
Public documents Approbation
  Information for the patient
  Informed consent
Last update 23/07/2021

 

Last updated on 30/08/2021